Abstract
In 2016 the World Health Organization updated the classification of central nervous system tumours to incorporate molecular analysis alongside histopathological evaluation. Under the revised system, diagnosis of oligodendroglioma requires presence of both an IDH mutation and codeletion of chromosomal regions 1p and 19q. In 2019, the All Wales Medical Genomics Service (AWMGS) introduced a bespoke multi-gene NGS panel for a range of tumour types, which included 10 genes/regions implicated in the diagnosis, prognosis and treatment of gliomas.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
